Clinical Significance and Management of Bigeminy in the CVICU

Presentation and Risk Stratification

Ventricular bigeminy can present with effective bradycardia, an apical-radial pulse deficit, and relative hypertension with a wide pulse pressure, according to the American Heart Association 1
Patients may have inaccurate heart rate estimation due to the effective bradycardia from PVCs, as noted by the American Heart Association 1
Bigeminy in patients with structural heart disease carries higher risk, as indicated by the American College of Cardiology and the American Heart Association 1, 2
Hemodynamic stability is a key factor in determining the seriousness of bigeminy, with bigeminy causing hemodynamic compromise requiring immediate attention, according to the American Heart Association 3
The context of bigeminy, such as in the setting of acute myocardial ischemia, electrolyte abnormalities, or drug toxicity, requires prompt intervention, as recommended by the American Heart Association 4

Evaluate for hemodynamic compromise, such as hypotension or decreased cardiac output, as recommended by the American Heart Association 3
Check for symptoms, such as dizziness, chest pain, or dyspnea, as indicated by the American College of Cardiology 2
Review recent medications, particularly those that can prolong QT interval, as recommended by the American Heart Association 1
Assess for electrolyte abnormalities, especially potassium and magnesium, as indicated by the American Heart Association 4
Obtain a 12-lead ECG during normal rhythm to look for evidence of underlying heart disease, as recommended by the American College of Cardiology 2
Measure QT interval carefully during periods of sinus rhythm, as indicated by the European Society of Cardiology 5
Consider echocardiography to evaluate for structural heart disease or ventricular dysfunction, as recommended by the European Society of Cardiology 5

Hemodynamic compromise due to bigeminy requires immediate treatment, as recommended by the American Heart Association 3
Correction of underlying causes, such as addressing electrolyte abnormalities or drug effects, is essential, as indicated by the American Heart Association 3
Antiarrhythmic therapy, such as beta-blockers, may be considered for symptomatic ventricular ectopy, as recommended by the American College of Cardiology 7
Other agents, such as lidocaine, procainamide, or amiodarone, may be considered for persistent, symptomatic bigeminy, as indicated by the American College of Cardiology 7

Ventricular arrhythmias in post-MI patients require careful monitoring, as they may indicate ongoing ischemia, as recommended by the American Heart Association 4
Bigeminy in patients with temporary pacemakers requires evaluation for lead dislodgement or sensing issues, as indicated by the American Heart Association 8
In patients with heart failure, bigeminy may be exacerbated by positive inotropic drugs with proarrhythmic properties, as noted by the American Heart Association 6